BanuAbbas(Karimi)Karimi-ShahMD
Pulmonology • Falls Church, VACritical Care Medicine, Pleural Disease
Physician
Are you Dr. Karimi-Shah?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 73 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3300 Gallows Road Department of Medicine
Falls Church, VA 22042Phone+1 703-776-3582
Summary
- Dr. Banu (Karimi) Karimi-Shah, MD is a pulmonologist in Falls Church, Virginia. She is currently licensed to practice medicine in Virginia, Maryland, and Massachusetts. She is affiliated with Inova Alexandria Hospital, Inova Mount Vernon Hospital, and Inova Loudoun Hospital.
Education & Training
Massachusetts General Hospital/BIDMC/Harvard Medical SchoolFellowship, Pulmonary Disease and Critical Care Medicine, 2003 - 2006- Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
Boston University School of MedicineClass of 2000
Certifications & Licensure
VA State Medical License 2009 - 2026
MD State Medical License 2008 - 2010
MA State Medical License 2002 - 2009- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- 18 citationsMeaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Sympo...Ganesh Raghu, Marya Ghazipura, Thomas R Fleming, Kerri I Aronson, Jürgen Behr
American Journal of Respiratory and Critical Care Medicine. 2024-03-15 - 595 citationsThe lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak.Andrew M. Tager, Peter LaCamera, Barry S. Shea, Gabriele S. V. Campanella, Moisés Selman
Nature Medicine. 2008-01-01 - 115 citationsAcute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary FibrosisMiya O Paterniti, Youwei Bi, Dinko Rekić, Yaning Wang, Banu A Karimi-Shah
Annals of the American Thoracic Society. 2017-09-01
Press Mentions
FDA Advisors Tepid on Drug Candidate for COVID InpatientsNovember 10th, 2022
FDA Approves Symdeko for Treatment of CF Children, Ages 6 to 11, with Certain CFTR MutationsJune 25th, 2019
FDA Expands Approval of CF Treatment to Include Patients Ages 6 and OlderJune 24th, 2019- Join now to see all
